View Older Stories View More Recent Stories
-
StreetInsider.com Premium Hot Research Recap 7/26
-
UPDATE: BMO Capital Upgrades C.H. Robinson Worldwide (CHRW) to Outperform
-
UPDATE: BMO Capital Downgrades AMD (AMD) to Market Perform
-
Encana Completes Sale of Its Piceance Natural Gas Assets
-
Eli Lilly & Co. (LLY): Stock Remains Overvalued - BMO
-
Tetraphase Pharmaceuticals (TTPH) PT Raised to $13 at BMO Capital
-
BMO Capital Downgrades Amgen (AMGN) to Market Perform
-
Calyxt Announces Full Exercise of Over-Allotment Option and Closing of its Initial Public Offering
-
Cellectis S.A.: Calyxt Announces Full Exercise of Over-Allotment Option and Closing of its Initial Public Offering
-
Ionis Pharmaceuticals (IONS) PT Raised to $67 at BMO Capital; Buy on Weakness
-
StreetInsider.com Premium Hot Research Recap 7/25
-
Ionis (IONS) Partner Biogen Reports Blow-Out Spinraza Sales - BMO Capital
-
QEP Resources (QEP) to Sell Natural Gas Assets In Southwest Wyoming for $777.5M
-
QEP Resources Announces Agreements to Sell Natural Gas Assets In Southwest Wyoming for $777.5 Million
-
Fifth Third Bancorp (FITB) PT Raised to $28 at BMO Capital on 2Q Report; 'Capital Return Is Now a Bigger Part of the Story'
-
Kansas City Southern (KSU) PT Raised to $105 at BMO Capital; 'Q217 Results Ahead of Expectations, Valuation Balanced'
-
Citizens Financial Group (CFG) PT Raised to $39 at BMO Capital on 2Q Report; 'Beat Driven by Lower Credit Costs & Better Fee Income'
-
Huntington Bancshares (HBAN) PT Lowered to $15 at BMO Capital on 2Q Report; 'Expenses Disappoint Again, but Loan Growth Should Pick Up'
-
Gentex (GNTX) PT Lowered to $22 at BMO Capital on 2Q Report; 'Oversold Following 2Q Miss, Outlook Remains Strong'
-
Merck (MRK) PT Lowered to $73 at BMO Capital Ahead of 2Q Announcement on 7/28 BMO; '2Q Should be In-Line'
-
StreetInsider.com Premium Hot Notes Recap 7/24
-
BMO Capital Upgrades Caterpillar (CAT) to Outperform
-
Global Medical REIT Inc. Announces Closing of Over-Allotment Option from Recent Common Stock Offering
-
UMH Properties, Inc. Prices Public Offering of 5,000,000 Shares of 6.75% Series C Cumulative Redeemable Preferred Stock
-
eBay (EBAY): Still Waiting For Inflection - BMO
-
Calyxt (CLXT) IPO Opens, Trades Higher
-
Morgan Stanley (MS) PT Raised to $61 at BMO Capital on 2Q Beat; 'Raising EstimatesFollowing Impressive Top-Line Beat'
-
UMH Properties, Inc. Announces Offering of Series C Cumulative Redeemable Preferred Stock
-
Qualcomm (QCOM): Significant Headwinds Remain - BMO
-
Cellectis S.A.: Calyxt Announces Pricing of $56.0 Million Initial Public Offering
-
Akcea Therapeutics (AKCA) Closes IPO, Reports $50M Private Placement with Novartis Pharma (NVS)
-
Akcea Therapeutics Announces Closing of Initial Public Offering
-
Regeneron (REGN): Raising PT On High Enthusiasm For Dupixent - BMO
-
UPDATE: BMO Capital Downgrades Chipotle Mexican Grill (CMG) to Market Perform
-
Vertex Pharma (VRTX): Raising PT Nearly 50% - BMO
-
World stocks tally ninth day of gains as earnings pick up
-
Dollar edges off lows against euro, central banks eyed
-
J&J sees sales growth in near-term; raises 2017 profit forecast
-
BMO Capital Downgrades Dominion Diamond (DDC) to Market Perform
-
Netflix (NFLX) PT Raised to $180 at BMO Capital
-
Platinum Group Metals Reports Third Quarter 2017 Results
-
ELS Reports Second Quarter Results
-
Akcea Therapeutics (AKCA) IPO Opens Modesty Higher
-
Shiloh Industries (SHLO) Prices 5M Share Common Offering at $8.25/Sh
-
Akcea Therapeutics (AKCA) Prices 15.625M Share IPO at $8/Sh
-
Shiloh Industries, Inc. Announces Pricing of Common Stock Offering
-
Akcea Therapeutics Announces Pricing of Initial Public Offering
-
If AstraZeneca (AZN) Soriot Rumors are True, It Becomes a Pfizer (PFE) Acquisition Target Again; Negative for Bristol-Myers (BMY)
-
Atalaya Mining PLC: Result of AGM
-
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $115 at BMO Capital; 'BMN 270 Succeeds at Mid & High Doses with Favorable Safety Profile... Probability of Success to 80%'


